# US 2013/0252898 A1 · Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252898 A1
- Document ID: US20130252898A1
- Status: Published application
- Kind: A1
- Application number: 13/906,074
- Filed: 2013-05-30
- Published: 2013-09-26
- Earliest claimed: 2010-06-24
- Assignees: Morehouse School of Medicine
- Applicants: Morehouse School Of Medicine
- Inventors: Gale W. Newman; Barbara A. Jacob-Mungin; Chamberlain Obialo
- Web page: https://patentgrep.com/patent/US20130252898A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/56988: {HIV or HTLV}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 33/78: Thyroid gland hormones {, e.g. T3, T4, TBH, TBG or their receptors}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/5754: Endothelin, vasoactive intestinal contractor [VIC]
- G01N 2800/28: Neurological disorders
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.

## Claims

### Claim 1

A method of treating HIV-associated nephropathy (HIVAN) or focal segmental glomerulosclerosis (FSGS), comprising administering to a mammalian subject an effective amount of a composition comprising an ET-1 antagonist, wherein the subject has an increased level of ET-1 compared to a control subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the control subject is an HIV positive subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ET-1 antagonist is a small molecule that binds to ET-1 or ET-1A.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ET-1 antagonist is selected from the group consisting of sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan and tezosentan.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ET-1 antagonist is administered by a local infusion into a kidney of the subject.

### Claim 6

A method for diagnosis of Nephropathy in a subject, comprising:
comparing a level of an ET-1-associated biomarker in a biological sample obtained from the subject to a threshold level; and
making a diagnosis based a result from the comparing step.

### Claim 7 (depends on 6)

The method of claim 6, wherein the biological sample is blood, plasma, urine, saliva or tissue.

### Claim 8 (depends on 6)

The method of claim 6, wherein the threshold level is a plasma ET-1 level at about 4 pg/ml and the subject is deemed to have a high risk of HIVAN and/or FSGS, if the plasma ET-1 level in the subject is higher than the threshold level.

### Claim 9 (depends on 6)

The method of claim 6, wherein the threshold level is a plasma ET-1 level at about 4.5 pg/ml and the subject is deemed to have a high risk of HIVAN and/or FSGS, if the plasma ET-1 level in the subject is higher than the threshold level.

### Claim 10 (depends on 6)

The method of claim 6, wherein said ET-1-associated biomarker is ET-1.

### Claim 11 (depends on 6)

The method of claim 6, wherein the level of the ET-1-associated biomarker is the ppET-1 mRNA level in peripheral blood derived macrophages that are harvested from the subject and cultured in the presence of HIV Nef.

### Claim 12 (depends on 6)

The method of claim 6, further comprising determining the level of the ET-1-associated biomarker in the biological sample for the subject.

### Claim 13 (depends on 6)

The method of claim 6, wherein said nephropathy is select from the group consisting of glomerulopathy, glomerulitis, glomerulonephritis, glomerulonephrosis, tubulitis, HIVAN, FSGS, Diabetic nephropathy, sickle cell nephropathy, renovascular hypertension, drug induced nephropathy, nephron loss, hyperfiltration, chronic pyelonephritis, Type I RPG/Type II hypersensitivity, Goodpasture's syndrome, Type II RPG/Type III hypersensitivity, Lupus (DPN), IgA/Berger's nephropathy, Wegener's granulomatosis, Microscopic polyangiitis, RTA (RTA 2), Fanconi syndrome, Bartter syndrome, Gitelman syndrome, Liddle's syndrome, RTA (RTA 1), diabetes insipidus (Nephrogenic), renal papilla, renal papillary necrosis, major calyx/pelvis, hydronephrosis, pyonephrosis, reflux nephropathy, acute tubular necrosis, interstitial nephritis, pyelonephritis, danubian endemic, familial nephropathy, renal failure, acute renal failure, chronic renal failure, uremic pericarditis, uremia, renal artery stenosis, renal ischemia, hypertensive nephropathy, renovascular hypertension, analgesic nephropathy, renal osteodystrophy, nephroptosis, and Abderhalden-Kaufmann-Lignac syndrome.

### Claim 14 (depends on 6)

The method of claim 6, wherein said nephropathy is HIVAN or FSGS.

### Claim 15

A composition for the treatment of HIVAN or FSGS, said composition comprising an ET-1 antagonist and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the ET-1 antagonist is a small molecule that binds to ET-1 or ET-1A.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the ET-1 antagonist is selected from the group consisting of sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan and tezosentan.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the composition is formulated for a route of administration selected from the group consisting of intravenous, intramuscular, nasal, transdermal, transmucosal, buccal, sublingual, oral, subdermal, or combination thereof.

### Claim 19

A kit for detecting the presence of an ET-1-associated biomarker in a biological sample, wherein said kit comprises one or more reagents suitable for measuring the ET-1-associated biomarker in the biological sample; and instructions for using said kit to detect said ET-1-associated biomarker, wherein the biological sample is blood, plasma, urine, saliva or tissue.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the reagents comprise an antibody, nucleic acid, or fragment thereof, wherein the antibody, nucleic acid, or fragment thereof specifically binds to the ET-1-associated biomarker.
